Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (Nasdaq: CADL) announced that CEO Paul Peter Tak will present and hold one-on-one investor meetings at two upcoming conferences.
Events include the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, at 10 AM ET and the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 5:30 PM ET. Live webcasts and 90-day replays will be available via the Investors section of candeltx.com.
Candel Therapeutics (Nasdaq: CADL) will host a webcast and conference call on May 15, 2026 at 1:00 PM ET to discuss extended follow-up data from the Phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer.
The discussion follows an oral plenary presentation at the American Urological Association 2026 Annual Meeting and will include commentary from leading prostate cancer specialists. The archived webcast will be available on the company's website for 90 days.
Candel Therapeutics (Nasdaq: CADL) announced on May 1, 2026 that its Compensation Committee granted inducement stock options on April 30, 2026 to two new employees for an aggregate of 29,400 shares at a per‑share exercise price of $6.18.
The options were granted under the company’s 2025 Inducement Plan (adopted December 24, 2025) and vest 25% after one year of service, with the remaining 75% vesting in 36 equal monthly installments, subject to continued employment. Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Candel Therapeutics (Nasdaq: CADL) signed a product commercialization agreement with EVERSANA to support a potential U.S. launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer. EVERSANA will provide data and analytics, medical affairs, market access, and field operations ahead of a planned BLA submission in Q4 2026.
This partner-led model complements existing work with IDEA Pharma and aims to preserve capital efficiency while preparing commercial capabilities subject to regulatory approval.
Candel Therapeutics (Nasdaq: CADL) announced inducement stock option grants on March 31, 2026 to five new employees totaling 70,000 options at a $4.90 exercise price.
The options were granted under the company’s 2025 Inducement Plan, adopted December 24, 2025, and vest 25% after one year, then monthly over 36 months, subject to continued service.
Candel Therapeutics (Nasdaq: CADL) reported extended follow-up from a Phase 2a study of aglatimagene besadenovec (CAN-2409) plus valacyclovir with continued ICI in advanced NSCLC. Among 46 per-protocol patients, 50% were alive at 24 months and median overall survival was 25.4 months.
Tumor biopsies showed increased pro-inflammatory gene expression and expanded T-cell receptor diversity, findings the company links to durable anti-tumor immunity. A pivotal Phase 3 trial in non-squamous NSCLC is planned to start in Q2 2026; FDA Fast Track designation is already in place.
Candel Therapeutics (Nasdaq: CADL) reported Q4 and full‑year 2025 results and corporate updates on March 12, 2026, highlighting clinical and financing milestones.
Key items: planned pivotal phase 3 NSCLC trial start in Q2 2026, a planned BLA submission for aglatimagene in Q4 2026, IND clearance for linoserpaturev (CAN-3110), a $130M term loan facility ( $50M drawn) and cash of $119.7M as of Dec 31, 2025 plus follow-on proceeds supporting runway into Q1 2028.
Candel Therapeutics (NASDAQ: CADL) will present updated, extended-follow-up data from its randomized Phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer at the AUA 2026 Annual Meeting in Washington, D.C., on May 15, 2026.
The oral plenary will report accumulating benefit for patients treated with CAN-2409 plus prodrug combined with standard external beam radiation; full abstracts and presentation details will be released at the event and posted by the company afterward.
Candel Therapeutics (Nasdaq: CADL) announced that on February 28, 2026 its Compensation Committee granted inducement stock options to one new employee to purchase 20,000 shares at an exercise price of $5.25 per share under the company's 2025 Inducement Plan.
Vesting: 25% after one year of service, then the remaining 75% vesting in 36 equal monthly installments, all subject to continued employment. The Plan was adopted on December 24, 2025 and the awards comply with Nasdaq Listing Rule 5635(c)(4).
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at TD Cowen’s 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026, 11:50 AM - 12:20 PM ET.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.candeltx.com, and a replay will be archived for up to 90 days after the session.